Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leo Gordon

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Leukemia Research|September 17, 2022
Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 studyShuo Ma, Steven T Rosen, Maria Winqvist, et al.
Genes, Chromosomes & Cancer|April 12, 2020
Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional studyLukas Streich, Madina Sukhanova, Xinyan Lu, et al.
Cancer|March 14, 2007
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipientsSteve Trifilio, Gennethel Pennick, Judy Pi, et al.
Database : the Journal of Biological Databases and Curation|February 21, 2016
Ensembl comparative genomics resourcesJavier Herrero, Matthieu Muffato, Kathryn Beal, et al.
Leukemia & Lymphoma|April 9, 2014
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomesOlga Frankfurt, Shuo Ma, Leo Gordon, et al.
Leukemia & Lymphoma|July 16, 2009
Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantationJayesh Mehta, Jayesh Mehta, Olga Frankfurt, et al.
Blood Advances|January 18, 2024
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimenReem Karmali, Carlos Galvez, Mehdi Hamadani, et al.
British Journal of Haematology|February 18, 2009
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trialOwen A O'Connor, Craig Moskowitz, Carol Portlock, et al.
Nucleic Acids Research|December 22, 2015
Ensembl 2016Andrew Yates, Wasiu Akanni, M Ridwan Amode, et al.
Nucleic Acids Research|October 30, 2014
Ensembl 2015Fiona Cunningham, M Ridwan Amode, Daniel Barrell, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Leukemia Research|September 17, 2022
Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 studyShuo Ma, Steven T Rosen, Maria Winqvist, et al.
Genes, Chromosomes & Cancer|April 12, 2020
Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional studyLukas Streich, Madina Sukhanova, Xinyan Lu, et al.
Cancer|March 14, 2007
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipientsSteve Trifilio, Gennethel Pennick, Judy Pi, et al.
Database : the Journal of Biological Databases and Curation|February 21, 2016
Ensembl comparative genomics resourcesJavier Herrero, Matthieu Muffato, Kathryn Beal, et al.
Leukemia & Lymphoma|April 9, 2014
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomesOlga Frankfurt, Shuo Ma, Leo Gordon, et al.
Leukemia & Lymphoma|July 16, 2009
Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantationJayesh Mehta, Jayesh Mehta, Olga Frankfurt, et al.
Blood Advances|January 18, 2024
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimenReem Karmali, Carlos Galvez, Mehdi Hamadani, et al.
British Journal of Haematology|February 18, 2009
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trialOwen A O'Connor, Craig Moskowitz, Carol Portlock, et al.
Nucleic Acids Research|December 22, 2015
Ensembl 2016Andrew Yates, Wasiu Akanni, M Ridwan Amode, et al.
Nucleic Acids Research|October 30, 2014
Ensembl 2015Fiona Cunningham, M Ridwan Amode, Daniel Barrell, et al.
Pageof 3